COMPANIES AND ACADEMICS IN RESIDENCE
Selected start-up companies, and junior academic research groups whose research interests are aligned with ours, are housed in the Centre for Pathway Analysis. Our Milner Therapeutics Consortium pharma partners also have a physical presence, through scientists working on collaborative projects with Cambridge researchers and through hot-desking.
Below you will find details of companies and academics who currently reside within the Milner Therapeutics Institute.
Rockend, co-founded by Dr James Patterson, is developing a next generation cell-based therapeutic. Their platform is based upon genetically engineered iPSCs, and makes use of multiple new advances across the synthetic biology and genome editing space.
Rockend Ltd aim to develop a non-immunogenic, intelligent and safe drug that could be used for the treatment of cancers, autoimmune diseases and various other unmet medical needs.
The Tzelepis group is focusing on the discovery of novel therapeutic targets and the bench-to-clinic transition of new treatments for aggressive malignancies including acute myeloid leukaemia (AML). Dr Tzelepis’s recent work has led to the development of sophisticated CRISPR screening platforms which formed the basis for his follow-up studies that identified the role of several new cancer vulnerabilities including the RNA methyltransferase METTL3 and the splicing kinase SRPK1. Now, his group is investigating how the structures and modifications of the RNA regulate the initiation and maintenance of devastated diseases.
- Yankova, Blackaby et al. Small molecule inhibition of METTL3 as a strategy against myeloid leukaemia. Nature 2021
- Mikutis et al. meCLICK-Seq – a substrate-hijacking and RNA degradation strategy for the study of RNA methylation. ACS Central Science 2020
Contact Konstantinos now by emailing firstname.lastname@example.org.
The Pathania group (Milner Therapeutics Institute, Dept Oncology and CRUK Cambridge Centre) have a central focus on developing new mouse models for children’s brain tumours, to better understand the diverse genetic basis of different brain tumour types. By applying CRISPR technology to test genetic and epigenetic weaknesses in these tumour models, they hope in the longer term to pave the way to more targeted, precise treatments that can be tailored to each patient. A key area of interest includes how dynamic chromatin remodelling is regulated in neural stem cells and how it becomes co-opted in brain cancer, including paediatric high-grade glioma.
Contact Manav now by emailing email@example.com.